Key result
Purified antithrombin III concentrate shows no difference in catabolism between healthy and congenitally deficient patients.
Why the study?
The catabolism of antithrombin III concentrate in healthy individuals and patients with congenital AT III deficiency, including the effect of warfarin, was not well characterized.
Does the catabolism of antithrombin III concentrate differ between healthy individuals and patients with congenital AT III deficiency, or when combined with warfarin?
Does the catabolism of antithrombin III concentrate differ between healthy individuals and patients with congenital AT III deficiency, or when combined with warfarin?
The catabolism of antithrombin III concentrate is similar in healthy individuals and those with congenital deficiency, and is not affected by concurrent warfarin use.
No takes yet. Share an insight, caveat, or question.
Similar half-life supports consistent dosing across groups; leaves open prospective validation including warfarin co-use.
Tengborn et al. (1981) studied Congenital antithrombin III deficiency (n=4). Purified radiolabelled antithrombin III (AT III) concentrate vs. Healthy normals; alone vs combined with warfarin was evaluated on Catabolic parameters including half-life. Purified radiolabelled antithrombin III concentrate had a half-life of 3.4 to 4.8 days, with no difference in catabolism between healthy normals and patients with congenital deficiency.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: